The market is weak to open as a follow through on the selling yesterday. This feels like a reversal day but it is way too early to tell but either way I think we are going to get a sense of how stocks are going to trade into the end of the year. A day […]
December 5 Biotech Update
Another day and another morning with an opening spike in large cap biotechs that was immediately sold. This is a disturbing pattern and one that needs to break if the sector is going to continue to move higher. Until we can get follow through on these opening moves, we are going to at best treat […]
December 1 Bitoech Update
Markets are weak and the biotech sector is moving with it and it appears that small cap and momentum plays are being most affected (large caps seem to be holding up fairly well). The market probably needs to consolidate its recent move as do a lot of biotechs but the wild cards this month are […]
November 26 Biotech Update
The trading is winding down as we approach Thanksgiving and I suspect today is going to be slow and get slower. The market will be open again on Friday but will likely be even slower as many will likely take the half trading day off. I suspect this also means that news flow will also […]
November 24 Biotech Update
A decent start to the week but volume is going to be low all week and I suspect that will increase the chop. So I would not read anything into the broader sector outside of this week having a slight positive bias. That being said, we do have to respect any move that is done […]
November 21 Biotech Update
A great open for the market but then it immediately proceeded to lay an egg. It is still early and the key is going to be how it responds to the selling. The only worrying sign is that the downdraft really seemed to hit biotechs and these have been a leading indicator of larger market […]
November 20 Biotech Update
Market starts a little weak this morning and generally is taking the sector with it. That being said it is not a rout by any means, so it seems like there sector is looking to find its footing before the next move. Luckily we have some news to talk about. 1. EPZM reported very positive […]
November 17 Biotech Update
This morning was just a little bit busy. The market was neutral, which gives us a nice clean way to see how the biotechs are reacting to news. In general, it appears that good news is still moving stocks higher, although some of the moves were more muted than you would expect. In any case, […]
November 14 Biotech Update
The markets are fine this morning but biotech is weak and seems to be led lower by GILD and other large caps. As long as GILD is weak it is going to be difficult for the sector to lead and this could eventually spill over into the broader markets. We have quickly moved from extremes […]
November 13 Biotech Update
A decent start to the market with biotech generally participating. GILD seems to remain the odd stock and continues to struggle at these levels for reasons that I will follow up on tomorrow. Sentiment seems to be changing in GILD and we certainly need to keep an eye on it even if you do not […]
November 10 Biotech Update
News continues to roll in and the market is providing a relatively neutral backdrop, which gives us a good sense of what the price action means. In other words, the price action of biotech stocks after news seems to be a clear signal of market reaction and is not being cloudy by macro effects. This […]
ABBV Survey Results [Free Content]
Earlier today on twitter there was a robust debate about the weakness seen in GILD and how this is related to fears on the upcoming competition from ABBV/ENTA. It seemed clear that there was a debate over the ultimate discount that ABBV was going to offer when compared to the GILD regime. While everyone had […]
November 5 Biotech Update
The markets seem to be in consolidation mode or to put it another way it is trying to make up its mind about the next move. At this point I am 50/50 on the next move as it really seems to be in no man’s land. The longer we stay at these levels the better […]
October 31 Biotech Update
A strong start to the morning but this seems a lot like a short term blow off rally but we need to see how the week closes. If we can end the day near the highs then I think the rally has some more legs in the near term but a close near the lows […]
October 29 Biotech Update
A little bit of consolidation in the sector, which seems perfectly healthy especially with the GILD “miss.” The broader markets are presenting a positive/neutral backdrop and I think that eventually leads to the sector playing catch up and then taking the lead. I still think we need to keep an eye on small caps as […]
October 24 Biotech Update
It was a neutral open for the market which is pretty positive given the selling related to the Ebola case in NYC. It is very positive to see the market shrug off the news as it now seems that the Ebola panic and fear is decreasing. I read that there are probably up to 8-10 […]
October 23 Bioech Update
The rebound is continuing with large caps continuing to lead but with good participation with the small caps, which is nice to see. It really is a little amazing to see how many V-shaped moves this market makes and how little memory it has day to day. In any case, I still think the path […]
[Free Content] TGTX in Pictures
TG Therapeutics has two programs, the CD20 targeting antibody TG-1101, and PI3K delta inhibitor TGR-1202. The focus of this post is on TGR-1202. Earlier coverage can be found here [link]. TG has been hesitant in giving out the structure of TGR-1202. It’s out now, so here it is below along with Idelalisib and IPI-145 […]
October 16 Biotech Update
The market continues its weakness but I am certainly encouraged that small caps are out performing. They were an early signal on the way down and so are potentially an early signal on the way back up. Of course, it could just be funds who were short are raising cash but I am not convinced […]
October 10 Biotech Update
I am still not convinced that the market is done correcting. Even if we have another rip roaring rally, it just seems like the path of least resistance over the near term is lower. In fact, I would not be surprised if we are not beginning the long awaited 10% correction. If that is the […]
